Table of Contents

State/Territory Name: Alabama

State Plan Amendment (SPA) #: 19-0010

This file contains the following documents in the order listed:

- 1) RO Follow-Up Approval Letter
- 2) Pharmacy Approval Letter
- 3) CMS 179 Form
- 4) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 61 Forsyth Street S.W. Suite 4T20 Atlanta, Georgia 30303

Atlanta Regional Operations Group

CENTERS FOR MEDICARE & MEDICAID SERVICES CENTER FOR MEDICAID & CHIP SERVICES

January 14, 2020

Stephanie McGee Azar, Commissioner Alabama Medicaid Agency 501 Dexter Avenue Montgomery, AL 36103-5624

Re: Alabama State Plan Amendment 19-0010

Dear Ms. Azar:

This is to affirm approval of the above-referenced State Plan Amendment, which was submitted to the Atlanta Regional Operations Group on November 19, 2019. The state's requested effective date of October 1, 2019 has been accepted.

Enclosed for your records are:

- 1. a copy of the approval letter dated January 13, 2020 that was submitted to the state by Cynthia Denemark, Deputy Director, Division of Pharmacy;
- 2. the original signed 179; and
- 3. the approved plan pages.

If you have any additional questions or need further assistance, please contact Alice Hogan at (404) 562-7432 or Alice.Hogan@cms.hhs.gov.

Sincerely,

/s/

Davida R. Kimble Acting Deputy Director Division of Medicaid Field Operations South

Enclosures



Center for Medicaid and CHIP Services

Disabled and Elderly Health Programs Group

January 13, 2020

Ms. Stephanie McGee Azar Commissioner Alabama Medicaid Agency 501 Dexter Avenue PO Box 5624 Montgomery, AL 36103-5624

Dear Ms. Azar:

The CMS Division of Pharmacy team has reviewed Alabama State Plan Amendment (SPA) 19-0010 received in the Atlanta Regional Operations Group on October 16, 2019. This SPA proposes to allow the state to comply with the Medicaid Drug Utilization Review (DUR) provisions included in Section 1004 of the Substance Use-Disorder Prevention that promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act (P.L. 115-271).

Based on the information provided and consistent with the regulations at 42 CFR 430.20, we are pleased to inform you that SPA 19-0010 is approved with an effective date of October 1, 2019. A copy of the signed CMS-179 form, as well as the pages approved for incorporation into Alabama's state plan will be forwarded by the Atlanta Regional Operations Group.

If you have any questions regarding this request, please contact Justin Aplin at (410) 786-6901 or Justin.Aplin@cms.hhs.gov.

Sincerely,

/s/

Cynthia R. Denemark, R.Ph. Deputy Director Division of Pharmacy DEHPG/CMCS/CMS

cc: Shantrina Roberts, Director, Atlanta Regional Operations Group Alice Hogan, Atlanta Regional Operations Group

DEPARTMENT OF HEALTH AND HUMAN SERVICES HEALTH CARE FINANCING ADMINISTRATION		FORM APPROVED OMB NO. 0938-0193			
TRANSMITTAL AND NOTICE OF APPROVAL OF	1. TRANSMITTAL NUMBER: AL-19-0010	2. STATE Alabama			
STATE PLAN MATERIAL	3. PROGRAM IDENTIFICATION: TIT	I E XIX OF THE			
FOR: HEALTH CARE FINANCING ADMINISTRATION	SOCIAL SECURITY ACT (MEDICAID)				
TO: REGIONAL ADMINISTRATOR	4. PROPOSED EFFECTIVE DATE				
HEALTH CARE FINANCING ADMINISTRATION	October 1, 2019				
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
5. TYPE OF PLAN MATERIAL (Check One):					
	CONSIDERED AS NEW PLAN	AMENDMENT			
COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AMEN		amendment)			
6. FEDERAL STATUTE/REGULATION CITATION: 42 CFR 456.703	7. FEDERAL BUDGET IMPACT: a. FFY 2019 0				
42 CFR 456.709	b. FFY 2020 0				
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:	9. PAGE NUMBER OF THE SUPERSI	EDED PLAN SECTION			
	OR ATTACHMENT (If Applicable):				
	Section 4.26 Page 74c				
Section 4.26 Page 74c	Section 4.20 Fage 740				
10. SUBJECT OF AMENDMENT:					
The primary purpose for this amendment is to bring the State Plan into ad (DUR) requirements included in Section 1004 of the Substance Use-Diso					
Patients and Communities (SUPPORT) Act.	ruer rievention that rionotes Opioid Rec	overy and Treatment for			
11. GOVERNOR'S REVIEW (Check One):	_				
GOVERNOR'S OFFICE REPORTED NO COMMENT	\boxtimes OTHER, AS SPECI				
☐ COMMENTS OF GOVERNOR'S OFFICE ENCLOSED ☐ NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	Governor's designe via letter with CM				
INO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	via letter with CM.	3			
12. SIGNATURE OF STATE AGENCY OFFICIAL:	16. RETURN TO:				
/s/	Stephanie McGee Azar				
13. TYPED NAME:	Commissioner				
Stephanie McGee Azar	Alabama Medicaid Agency 501 Dexter Avenue				
14. TITLE:	Post Office Box 5624				
Commissioner	Montgomery, Alabama 36103-5624				
15. DATE SUBMITTED:					
FOR REGIONAL OFFICE USE ONLY					
17. DATE RECEIVED: 11/19/19	18. DATE APPROVED: 01/13/20				
PLAN APPROVED – ONE COPY ATTACHED					
19. EFFECTIVE DATE OF APPROVED MATERIAL:	20. SIGNATURE OF REGIONAL OFF	FICIAL:			
10/01/19	/s/				
21. TYPED NAME: Davida R. Kimble	22. TITLE: Acting Deputy Director				
22 DEMADKO.	Division of Medicaid Field Operations S	South			
23. REMARKS:					

74c

OMB

STATE / TERRITORY <u>Alabama</u>

Citation	

Citation			
1927 (g) (3) (C) 42 CFR 456.711 (a)-(d)		G.4.	The interventions include in appropriate instances: - Information dissemination - Written, oral and electronic reminders - Face-to-Face discussions - Intensified monitoring/ review of prescribers/ dispensers
1927 (g) (3) (D) 42 CFR 456.712 (A) and (B)		H.	The State assures that it will prepare and submit an annual report to the Secretary, which incorporates a report from the State DUR Board, and that the State will adhere to the plans, steps, procedures as described in the report.
1902(a)(85) and Section 1004 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act)		I.	 Claim Review Limitations Prospective safety edits on opioid prescriptions to address days' supply, early refills, duplicate fills and quantity limitations for clinical appropriateness. Prospective safety edits on maximum daily morphine milligram equivalents (MME) on opioids prescriptions to limit the daily morphine milligram equivalent on opioids prescription to limit the daily morphine equivalent (as recommended by clinical guidelines). Retrospective reviews on opioid prescriptions exceeding these above limitations on an ongoing basis. Retrospective reviews on concurrent utilization of opioids and benzodiazepines as well as opioids and antipsychotics on an ongoing periodic basis. Programs to monitor antipsychotic medications to children. Antipsychotic agents are reviewed for appropriateness for all children including foster children based on approved indications: The DUR/Lock-In program has established a process that identifies potential fraud or abuse of controlled substances by enrolled individuals, health care providers and pharmacies.
1927 (h) (1) 42 CFR 456.722	<u>X</u>	I.1	The State establishes, as its principal means of processing claims for covered outpatient drugs under this title, a point-of-sale electronic claim management system to perform on-line: - real time eligibility verification - claims data capture - adjudication of claims - assistance to pharmacies, etc. applying for and receiving payment.
1927 (g) (2) (A) (i) 42 CFR 456.705 (b)	<u>X</u>	2.	Prospective DUR is performed using an electronic point of sale drug claims processing system.
1927 (j) (2) 42 CFR 456.703 (c)		J.	Hospitals which dispense covered outpatient drugs are exempted from the drug utilization review requirements of this section when facilities use drug formulary systems and bill the Medicaid program no more than the hospital's purchasing cost for such covered outpatient drugs.